Healthcare - Biotechnology - NASDAQ - US
$ 13.97
-7.61 %
$ 1.42 B
Market Cap
-2.56
P/E
INCOME STATEMENT
36.3 M
REVENUE
-515 M
OPERATING INCOME
-481 M
NET INCOME
EFFICIENCY
Earnings Waterfall
Intellia Therapeutics, Inc.
| Revenue | 36.3 M |
| Cost Of Revenue | 435 M |
| Gross Profit | -399 M |
| Operating Expenses | 552 M |
| Operating Income | -515 M |
| Other Expenses | -34.1 M |
| Net Income | -481 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||
| Revenue | 36.3 | 52.1 | 33.1 | 58.0 | 43.1 | 30.4 | 26.1 | 16.5 | 6.0 | 0 |
| GROSS PROFIT | ||||||||||
| Cost Of Revenue | 435.1 | 7.6 | 6.9 | 150.4 | 108.4 | 89.1 | 67.6 | 31.8 | 11.2 | 1.7 |
| Gross Profit | (398.8) | 44.5 | 26.2 | (92.4) | (65.3) | (58.7) | (41.5) | (15.4) | (5.1) | (1.7) |
| OPERATING INCOME | ||||||||||
| Operating Expenses | 551.6 | 510.3 | 300.9 | 194.6 | 149.5 | 121.3 | 95.7 | 48.6 | 19.5 | 12.7 |
| Selling, General and Administrative Expenses | 116.5 | 90.3 | 71.1 | 44.2 | 41.1 | 32.2 | 28.0 | 16.8 | 8.3 | 3.6 |
| Research and Development Expenses | 435.1 | 420.0 | 229.8 | 150.4 | 108.4 | 89.1 | 67.6 | 31.8 | 11.2 | 10.7 |
| Operating Income | (515.3) | (458.2) | (267.9) | (136.6) | (106.4) | (90.9) | (69.6) | (32.2) | (13.4) | (5.2) |
| PRE-TAX INCOME | ||||||||||
| Interest Income Expense | 0 | 8.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income | 34.1 | (16.0) | 42 K | 2.4 | 6.8 | 5.5 | 2.0 | 0.5 | 0 | (9.1) |
| Pre-Tax Income | (481.2) | (474.2) | (267.9) | (134.2) | (99.5) | (85.3) | (67.5) | (31.6) | (13.4) | (14.3) |
| NET INCOME | ||||||||||
| Tax Provision | 0 | 16.0 | (8.2) | (8.7) | (6.8) | 5.5 | (3.0) | (1.1) | (1.0) | 0 |
| Net Income | (481.2) | (490.2) | (259.7) | (125.6) | (92.7) | (85.3) | (67.5) | (31.6) | (12.4) | (14.3) |
| EPS | 5.42 | 6.37 | 3.66 | 2.24 | 1.96 | 1.98 | 1.88 | 1.42 | 0.7 | 29.4 |